Taiwan Bio Therapeutics (ROCO:6892) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6892 Taiwan Bio Therapeutics Inc ROCO:6892
14 GF Score
Price NT$25.20
GF Value NT$14.55
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Taiwan Bio Therapeutics Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

ROCO:6892
14GF Score
Taiwan Bio Therapeutics Inc ROCO:6892
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Taiwan Bio Therapeutics (ROCO:6892) Overvalued in 2026?

Based on GuruFocus' analysis, Taiwan Bio Therapeutics stock appears to be overvalued. The current stock price of NT$25.20 is trading 73.2% above its estimated GF Value™ of NT$14.55. GuruFocus considers Taiwan Bio Therapeutics to be Significantly Overvalued.

Key valuation signals for ROCO:6892:

  • Dividends Received:
  • GF Value™: NT$14.55 vs. price of NT$25.20 (73.2% above fair value)
  • GF Score™: 14/100 with 5 warning signs

No single metric tells the full story. See the ROCO:6892 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Taiwan Bio Therapeutics Business Description

Address Tiding Avenue, 5th Floor, No. 501, Section 2, Neihu District, Zhubei, TWN, 114744
Taiwan Bio Therapeutics Inc is a regenerative medicine company specializing in the development of new genetically modified cell drugs. It is providing commissioned development and manufacturing (CDMO/CMO) services and inspection, analysis and development services for cellular medical products.
14GF Score

Get the complete analysis for ROCO:6892

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$25.20
Price
NT$14.55
GF Value